Key Segmentation
By Biomarker Type
-
Serum Biomarkers
-
Hepatic Fibrosis Biomarkers
-
Oxidative Stress Biomarkers
-
Apoptosis Biomarkers
-
Genomic/Proteomic Biomarkers
-
Others
By Diagnostic Technique
-
Imaging Biomarkers
-
Serum-Based Testing
-
Histological Biomarkers
By Application
-
Drug Development
-
Clinical Diagnosis
-
Research Applications
By End User
-
Pharmaceutical Companies & CROs
-
Research Institutes & Academics
-
Hospitals & Diagnostic Centres
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is expected to grow at a CAGR of 25.9% from 2026 to 2035.
The Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market was valued at USD 1.81 Billion in 2025.
Rising global NASH prevalence driven by the obesity epidemic creating a structurally growing diagnostic unmet need.
Serum Biomarkers dominated the Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market with approximately 32.51% share in 2025, while Hepatic Fibrosis Biomarkers is the fastest growing.
North America dominated the Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market in 2023 with approximately 40% of overall market share, with the United States accounting for approximately 87.4% of North American revenues.